Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Thrombotic thrombocytopenic" to "[[Category:Acquired thrombotic thrombocytopenic") |
||
| (14 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
A [https://en.wikipedia.org/wiki/Single-domain_antibody single domain antibody] directed against the A1 domain of von Willebrand factor (vWF). | A [https://en.wikipedia.org/wiki/Single-domain_antibody single domain antibody] directed against the A1 domain of von Willebrand factor (vWF). | ||
| − | = | + | ==Diseases for which it is used== |
| + | *[[Acquired thrombotic thrombocytopenic purpura]] | ||
| − | ==[[ | + | ==History of changes in FDA indication== |
| − | + | * 2019-02-06: Initial approval for adult patients with [[Acquired thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | |
| + | ==History of changes in EMA indication== | ||
| + | *2018-08-30: Initial authorization | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2022-09-26: A drug with a new active ingredient indicated for the treatment of [[Acquired thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura]]. | ||
| + | == Patient Drug Information== | ||
| + | *[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]<ref>[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]</ref><ref>[[:File:Cablivi.pdf | Caplacizumab (Cablivi) package insert (locally hosted backup)]]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' ALX-0081 | ||
| + | *'''Generic name:''' caplacizumab-yhdp | ||
| + | *'''Brand name:''' Cablivi | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
| + | [[Category:Subcutaneous medications]] | ||
| + | |||
[[Category:Anti-vWF medications]] | [[Category:Anti-vWF medications]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Acquired thrombotic thrombocytopenic purpura medications]] |
| − | [[Category: | + | [[Category:EMA approved in 2019]] |
| + | [[Category:FDA approved in 2019]] | ||
Latest revision as of 13:21, 7 June 2023
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2019-02-06: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
History of changes in EMA indication
- 2018-08-30: Initial authorization
History of changes in PMDA indication
- 2022-09-26: A drug with a new active ingredient indicated for the treatment of acquired thrombotic thrombocytopenic purpura.
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi